JP2017535246A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017535246A5 JP2017535246A5 JP2017512808A JP2017512808A JP2017535246A5 JP 2017535246 A5 JP2017535246 A5 JP 2017535246A5 JP 2017512808 A JP2017512808 A JP 2017512808A JP 2017512808 A JP2017512808 A JP 2017512808A JP 2017535246 A5 JP2017535246 A5 JP 2017535246A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- set forth
- sequence set
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical group 0.000 claims 114
- 239000000611 antibody drug conjugate Substances 0.000 claims 17
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 17
- 206010028980 Neoplasm Diseases 0.000 claims 13
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 12
- 201000011510 cancer Diseases 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 8
- 229940127089 cytotoxic agent Drugs 0.000 claims 7
- 239000002254 cytotoxic agent Substances 0.000 claims 7
- 231100000599 cytotoxic agent Toxicity 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 101000798109 Homo sapiens Melanotransferrin Proteins 0.000 claims 6
- 102100032239 Melanotransferrin Human genes 0.000 claims 6
- 208000000453 Skin Neoplasms Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 201000000849 skin cancer Diseases 0.000 claims 5
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims 4
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims 4
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical compound C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 claims 4
- 210000005102 tumor initiating cell Anatomy 0.000 claims 4
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 2
- 108010027164 Amanitins Proteins 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 101100261262 Homo sapiens MELTF gene Proteins 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 2
- CIORWBWIBBPXCG-JZTFPUPKSA-N amanitin Chemical compound O=C1N[C@@H](CC(N)=O)C(=O)N2CC(O)C[C@H]2C(=O)N[C@@H](C(C)[C@@H](O)CO)C(=O)N[C@@H](C2)C(=O)NCC(=O)N[C@@H](C(C)CC)C(=O)NCC(=O)N[C@H]1CS(=O)C1=C2C2=CC=C(O)C=C2N1 CIORWBWIBBPXCG-JZTFPUPKSA-N 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 108010044540 auristatin Proteins 0.000 claims 2
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims 2
- 229930195731 calicheamicin Natural products 0.000 claims 2
- 239000003638 chemical reducing agent Substances 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical group CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 claims 2
- 229930188854 dolastatin Natural products 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 claims 2
- 229960005501 duocarmycin Drugs 0.000 claims 2
- 229930184221 duocarmycin Natural products 0.000 claims 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- -1 maytansinoid Natural products 0.000 claims 2
- 208000021039 metastatic melanoma Diseases 0.000 claims 2
- 229940125645 monoclonal antibody drug Drugs 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 230000002285 radioactive effect Effects 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- 108010024636 Glutathione Proteins 0.000 claims 1
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 229960004308 acetylcysteine Drugs 0.000 claims 1
- 150000001412 amines Chemical group 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 230000004611 cancer cell death Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000001268 conjugating effect Effects 0.000 claims 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 229960002433 cysteine Drugs 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 229960003180 glutathione Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 238000004237 preparative chromatography Methods 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462046610P | 2014-09-05 | 2014-09-05 | |
| US62/046,610 | 2014-09-05 | ||
| US201562203836P | 2015-08-11 | 2015-08-11 | |
| US62/203,836 | 2015-08-11 | ||
| PCT/US2015/048659 WO2016037119A1 (en) | 2014-09-05 | 2015-09-04 | Novel anti-mfi2 antibodies and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017535246A JP2017535246A (ja) | 2017-11-30 |
| JP2017535246A5 true JP2017535246A5 (enExample) | 2019-04-25 |
Family
ID=55440418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017512808A Pending JP2017535246A (ja) | 2014-09-05 | 2015-09-04 | 新規の抗ｍｆｉ２抗体および使用方法 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US10428156B2 (enExample) |
| EP (1) | EP3189079A4 (enExample) |
| JP (1) | JP2017535246A (enExample) |
| KR (1) | KR20170045351A (enExample) |
| CN (1) | CN107001454A (enExample) |
| AU (1) | AU2015311743A1 (enExample) |
| BR (1) | BR112017004444A2 (enExample) |
| CA (1) | CA2959705A1 (enExample) |
| CL (2) | CL2017000506A1 (enExample) |
| CO (1) | CO2017003005A2 (enExample) |
| CR (1) | CR20170117A (enExample) |
| DO (1) | DOP2017000052A (enExample) |
| EA (1) | EA201790529A1 (enExample) |
| IL (1) | IL250825A0 (enExample) |
| MA (1) | MA40612A (enExample) |
| MX (1) | MX2017002862A (enExample) |
| PE (1) | PE20170776A1 (enExample) |
| PH (1) | PH12017500406A1 (enExample) |
| SG (1) | SG11201701650PA (enExample) |
| TW (1) | TW201617368A (enExample) |
| WO (1) | WO2016037119A1 (enExample) |
| ZA (1) | ZA201701674B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA127341C2 (uk) | 2016-04-15 | 2023-07-26 | Мекроудженікс, Інк. | Виділена b7-н3-зв'язувальна молекула |
| EP3760641A4 (en) * | 2018-02-27 | 2021-11-24 | Eisai R&D Management Co., Ltd. | MONOCLONAL ANTIBODIES AGAINST APOA4, IMMUNOASSAY AND KIT FOR MEASUREMENT |
| IL277095B2 (en) * | 2018-03-07 | 2025-10-01 | Pfizer | Preparations containing anti-PD-1 antibody |
| WO2020021556A1 (en) * | 2018-07-26 | 2020-01-30 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Compositions targeting gabra2 and methods for diagnosis and treatment of cancer |
| KR20210117276A (ko) * | 2018-12-21 | 2021-09-28 | 사프렘 테크놀로지스 비.브이. | 생물학적 활성 분자 클러스터 |
| CN109709340B (zh) * | 2018-12-29 | 2022-02-11 | 江苏众红生物工程创药研究院有限公司 | 人中性粒细胞明胶酶相关脂质运载蛋白定量检测卡及其临床应用 |
| WO2020150282A1 (en) * | 2019-01-18 | 2020-07-23 | Askgene Pharma Inc. | Pd-l1 specific monoclonal antibodies for disease treatment and diagnosis |
| AU2020219732A1 (en) * | 2019-02-05 | 2021-08-05 | Seagen Inc. | Anti-CD228 antibodies and antibody-drug conjugates |
| WO2021007533A1 (en) * | 2019-07-11 | 2021-01-14 | Tavotek Biotherapeutics (Hong Kong) Limited | Agents that interfere with thymic stromal lymphopoietin (tslp)-receptor signaling |
| GB201913594D0 (en) * | 2019-09-20 | 2019-11-06 | Univ Birmingham | Epigenetic profiling method |
| CN111909933B (zh) * | 2020-06-29 | 2021-07-02 | 浙江大学 | 靶向细胞表面抗原mfi2蛋白的核酸适配体及应用 |
| CN116568337A (zh) * | 2020-08-04 | 2023-08-08 | 思进股份有限公司 | 抗cd228抗体和抗体-药物缀合物 |
| WO2022187050A1 (en) * | 2021-03-01 | 2022-09-09 | BioLegend, Inc. | Anti-cd117 agents and compositions and methods for making and using the same |
| CN116925216B (zh) * | 2022-04-11 | 2024-09-24 | 东莞市朋志生物科技有限公司 | 抗血清淀粉样蛋白a抗体、检测血清淀粉样蛋白a的试剂和试剂盒 |
| IL319270A (en) * | 2022-09-21 | 2025-04-01 | Seagen Inc | Antibodies that bind CD228 |
| WO2025025731A1 (zh) * | 2023-07-28 | 2025-02-06 | 山东博安生物技术股份有限公司 | 一种适用于免疫组化检测cd228的诊断抗体 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| USRE38008E1 (en) | 1986-10-09 | 2003-02-25 | Neorx Corporation | Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5191066A (en) | 1990-12-07 | 1993-03-02 | Abbott Laboratories | Site-specific conjugation of immunoglobulins and detectable labels |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| US6146850A (en) | 1991-11-04 | 2000-11-14 | Xoma Corporation | Proteins encoding gelonin sequences |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5981194A (en) | 1992-07-10 | 1999-11-09 | University Of British Columbia | Use of p97 and iron binding proteins as diagnostic and therapeutic agents |
| CA2140280A1 (en) | 1992-08-17 | 1994-03-03 | Avi J. Ashkenazi | Bispecific immunoadhesins |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| US6329179B1 (en) | 1996-03-26 | 2001-12-11 | Oncomedx, Inc. | Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer |
| US6753165B1 (en) | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
| ES2375931T3 (es) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | Humanización de anticuerpo murino. |
| WO1999037779A1 (en) | 1998-01-22 | 1999-07-29 | Genentech, Inc. | Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies and uses of same |
| ES2244210T3 (es) | 1998-08-27 | 2005-12-01 | Spirogen Limited | Pirrolobenzodiazepinas. |
| NZ539776A (en) | 1999-01-15 | 2006-12-22 | Genentech Inc | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| JP4414023B2 (ja) * | 1999-08-05 | 2010-02-10 | オリエンタル酵母工業株式会社 | 関節炎関連メラノトランスフェリンの測定方法および試薬 |
| WO2001059459A2 (en) | 2000-02-08 | 2001-08-16 | University Of British Columbia | Compositions and methods for screening therapeutic agents |
| KR20020007432A (ko) * | 2000-07-13 | 2002-01-29 | 박현석 | 멜라노트랜스페린에 대한 단클론 항체를 유효성분으로포함하는 알츠하이머병의 진단시약 |
| CA2431600C (en) | 2000-12-12 | 2012-04-17 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| US6362331B1 (en) | 2001-03-30 | 2002-03-26 | Council Of Scientific And Industrial Research | Process for the preparation of antitumor agents |
| EP1256354A1 (en) | 2001-05-11 | 2002-11-13 | Schering Corporation | Methods for treating cancer |
| TW200303759A (en) | 2001-11-27 | 2003-09-16 | Schering Corp | Methods for treating cancer |
| CN101987871A (zh) | 2002-09-27 | 2011-03-23 | 赞科股份有限公司 | 优化的Fc变体及其产生方法 |
| CA2499300A1 (en) | 2002-10-31 | 2004-05-21 | Genentech, Inc. | Methods and compositions for increasing antibody production |
| EP1419786A1 (en) | 2002-11-13 | 2004-05-19 | Bracco Imaging S.p.A. | Method for the selective and quantitative functionalization of immunoglobulin fab fragments, conjugate compounds obtained with the same and compositions thereof |
| GB0226593D0 (en) | 2002-11-14 | 2002-12-24 | Consultants Ltd | Compounds |
| ES2897506T3 (es) | 2003-01-09 | 2022-03-01 | Macrogenics Inc | Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos |
| WO2004099410A2 (en) * | 2003-05-09 | 2004-11-18 | Transfert Plus | Compound and method for regulating plasminogen activation and cell migration |
| WO2004101756A2 (en) | 2003-05-09 | 2004-11-25 | Diadexus, Inc. | Ovr110 antibody compositions and methods of use |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| AU2004273791A1 (en) | 2003-09-05 | 2005-03-31 | Genentech, Inc. | Antibodies with altered effector functions |
| GB0321295D0 (en) | 2003-09-11 | 2003-10-15 | Spirogen Ltd | Synthesis of protected pyrrolobenzodiazepines |
| US7807392B1 (en) | 2003-09-15 | 2010-10-05 | Celera Corporation | Lung disease targets and uses thereof |
| GB0404577D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
| PT2270010E (pt) | 2004-03-01 | 2012-03-12 | Spirogen Ltd | Derivados de 11-hidroxi-5h-pirrolo[2,1-c][1,4]benzodiazepin- 5-ona como intermediários chave para a preparação de pirrolobenzodiazepinas substituídas em c2 |
| AU2005218642B2 (en) | 2004-03-02 | 2011-04-28 | Seagen Inc. | Partially loaded antibodies and methods of their conjugation |
| US7189710B2 (en) | 2004-03-30 | 2007-03-13 | Council Of Scientific And Industrial Research | C2-fluoro pyrrolo [2,1−c][1,4]benzodiazepine dimers |
| FR2869231B1 (fr) | 2004-04-27 | 2008-03-14 | Sod Conseils Rech Applic | Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine |
| BRPI0516284A (pt) | 2004-09-23 | 2008-09-02 | Genentech Inc | anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto |
| EP1817341A2 (en) | 2004-11-29 | 2007-08-15 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
| DK1874821T3 (da) | 2005-04-26 | 2013-07-08 | Trion Pharma Gmbh | Kombination af antistoffer med glykokortikoider til behandling af kræft |
| US8008443B2 (en) | 2005-04-26 | 2011-08-30 | Medimmune, Llc | Modulation of antibody effector function by hinge domain engineering |
| GB0514779D0 (en) | 2005-07-19 | 2005-08-24 | Celltech R&D Ltd | Biological products |
| US7521195B1 (en) | 2005-07-21 | 2009-04-21 | Celera Corporation | Lung disease targets and uses thereof |
| US20070123448A1 (en) | 2005-11-23 | 2007-05-31 | The Hospital For Sick Children | Novel chemical entities affecting neuroblastoma tumor-initiating cells |
| ATE527262T1 (de) | 2006-01-25 | 2011-10-15 | Sanofi Sa | Neue tomaymycin derivate enhaltende zytotoxische mittel |
| PT2032606E (pt) | 2006-05-30 | 2014-02-05 | Genentech Inc | Anticorpos e imunoconjugados e respetivas utilizações |
| WO2007145901A1 (en) | 2006-06-06 | 2007-12-21 | University Of Tennessee Research Foundation | Compositions enriched in neoplastic stem cells and methods comprising same |
| US20080220448A1 (en) | 2006-09-01 | 2008-09-11 | Blincko Stuart J | Antigenic protein conjugates and process for preparing same |
| US7763242B2 (en) | 2006-09-07 | 2010-07-27 | Scott and White Memorial Hospital | Methods for treating myelodysplastic syndrome with a human interleukin-3-diphtheria toxin conjugate |
| GB0619291D0 (en) | 2006-09-29 | 2006-11-08 | Ucb Sa | Altered antibodies |
| EP2109668A4 (en) | 2007-01-22 | 2011-10-05 | Macrogenics West Inc | HUMAN CANCER STEM CELLS |
| CN101687037B (zh) | 2007-05-08 | 2013-07-10 | 健泰科生物技术公司 | 半胱氨酸改造的抗muc16抗体和抗体药物偶联物 |
| EP2022848A1 (en) | 2007-08-10 | 2009-02-11 | Hubrecht Institut | A method for identifying, expanding, and removing adult stem cells and cancer stem cells |
| EP2185188B1 (en) | 2007-08-22 | 2014-08-06 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
| WO2009032782A2 (en) | 2007-08-28 | 2009-03-12 | Biogen Idec Ma Inc. | Compositions that bind multiple epitopes of igf-1r |
| ES3006441T3 (en) | 2007-09-14 | 2025-03-18 | Amgen Inc | Homogeneous antibody populations |
| US20090155255A1 (en) | 2007-09-27 | 2009-06-18 | Biogen Idec Ma Inc. | Cd23 binding molecules and methods of use thereof |
| ES2613963T3 (es) | 2008-01-18 | 2017-05-29 | Medimmune, Llc | Anticuerpos manipulados con cisteína para conjugación específica de sitio |
| US20100162416A1 (en) | 2008-09-29 | 2010-06-24 | Stemlifeline, Inc. | Multi-stage stem cell carcinogenesis |
| US20120071634A1 (en) | 2009-03-19 | 2012-03-22 | Chugai Seiyaku Kabushiki Kaisha | Antibody Constant Region Variant |
| US20110020221A1 (en) | 2009-04-09 | 2011-01-27 | The Johns Hopkins University | Cancer stem cell expression patterns and compounds to target cancer stem cells |
| CA2790401C (en) | 2010-02-21 | 2018-05-29 | Bayer Healthcare Llc | Method for activation and conjugation of biomolecules |
| JP5889181B2 (ja) | 2010-03-04 | 2016-03-22 | 中外製薬株式会社 | 抗体定常領域改変体 |
| EP2558475A1 (en) | 2010-04-15 | 2013-02-20 | Spirogen Sàrl | Pyrrolobenzodiazepines used to treat proliferative diseases |
| MX2012011900A (es) * | 2010-04-15 | 2013-03-21 | Seattle Genetics Inc | Conjugados de pirrolobenzodiazepina diana. |
| NZ602241A (en) | 2010-04-15 | 2015-03-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| GB201006340D0 (en) | 2010-04-15 | 2010-06-02 | Spirogen Ltd | Synthesis method and intermediates |
| SG185428A1 (en) | 2010-06-08 | 2012-12-28 | Genentech Inc | Cysteine engineered antibodies and conjugates |
| EP2611463A2 (en) | 2010-09-03 | 2013-07-10 | Stem Centrx, Inc. | Identification and enrichment of cell subpopulations |
| US20130061342A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc. | Identification and Enrichment of Cell Subpopulations |
| US9778264B2 (en) | 2010-09-03 | 2017-10-03 | Abbvie Stemcentrx Llc | Identification and enrichment of cell subpopulations |
| WO2013119964A2 (en) | 2012-02-08 | 2013-08-15 | Stem Centrx, Inc. | Identification and enrichment of cell subpopulations |
| US20130061340A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc. | Identification and Enrichment of Cell Subpopulations |
| EP2617730B1 (en) | 2010-09-17 | 2018-03-07 | National Institute of Advanced Industrial Science And Technology | Lung cancer differential marker |
| EP2638066A4 (en) | 2010-11-09 | 2015-06-03 | Medimmune Llc | ANTIBODY EQUIPMENT FOR HOMOGENEOUS CONJUGATION |
| CA2820630A1 (en) | 2010-12-09 | 2012-06-14 | Bayer Healthcare Llc | Dimeric molecular complexes with free cysteine residues and conjugates thereof |
| HUE036229T2 (hu) | 2011-03-02 | 2018-06-28 | Roche Glycart Ag | CEA antitestek |
| HUE029855T2 (en) * | 2011-07-05 | 2017-04-28 | Bioasis Technologies Inc | p97 antibody conjugates |
| PT2739649T (pt) | 2011-08-05 | 2018-01-03 | Bioasis Technologies Inc | Fragmentos de p97 com atividade de transferência |
| JP2014530825A (ja) | 2011-10-19 | 2014-11-20 | セラテクノロジーズ・インコーポレーテッド | メラノトランスフェリン由来のペプチド化合物及びその使用 |
| KR20110136776A (ko) * | 2011-12-12 | 2011-12-21 | 경북대학교 산학협력단 | 당뇨병성 신증 진단용 바이오마커 및 이의 동정방법 |
| CN104011221B (zh) | 2011-12-20 | 2019-01-08 | 米迪缪尼有限公司 | 用于双特异性抗体支架的经修饰的多肽 |
| JP2015502397A (ja) | 2011-12-23 | 2015-01-22 | ファイザー・インク | 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用 |
| KR102099073B1 (ko) * | 2012-02-24 | 2020-04-10 | 애브비 스템센트알엑스 엘엘씨 | 항 ｓｅｚ6 항체들 및 사용 방법 |
| HK1203972A1 (en) | 2012-03-08 | 2015-11-06 | Halozyme, Inc. | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
| AU2013243955B2 (en) | 2012-04-02 | 2018-02-22 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
| US9504756B2 (en) | 2012-05-15 | 2016-11-29 | Seattle Genetics, Inc. | Self-stabilizing linker conjugates |
| WO2013177481A1 (en) | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazepines and conjugates thereof |
| AU2013292309B2 (en) * | 2012-07-20 | 2017-05-25 | Cleave Biosciences, Inc. | Fused pyrimidines as inhibitors of p97 complex |
| EP2905290B1 (en) | 2012-10-05 | 2019-12-04 | Kyowa Kirin Co., Ltd. | Heterodimeric protein composition |
| CA2885340C (en) | 2012-10-12 | 2016-11-08 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| PT3470086T (pt) | 2012-10-12 | 2021-02-01 | Medimmune Ltd | Pirrolobenzodiazepinas e conjugados das mesmas |
| ES2874493T3 (es) | 2013-02-08 | 2021-11-05 | Novartis Ag | Sitios específicos para modificar anticuerpos para generar inmunoconjugados |
| KR20160037130A (ko) | 2013-02-22 | 2016-04-05 | 스템센트알엑스 인코포레이티드 | 신규한 항체 접합체 및 이의 용도 |
| JP6586412B2 (ja) | 2013-03-13 | 2019-10-02 | バイオアシス テクノロジーズ インコーポレイテッド | ｐ９７のフラグメントおよびその使用 |
| CN116063479A (zh) | 2013-06-04 | 2023-05-05 | 西托姆克斯治疗公司 | 用于缀合可活化抗体的组合物和方法 |
| US9944931B2 (en) | 2013-06-10 | 2018-04-17 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for reducing immunosupression by tumor cells |
| CN105764501A (zh) | 2013-07-26 | 2016-07-13 | 现代化制药公司 | 改善比生群治疗效益的组合物 |
| EP3038657A2 (en) | 2013-08-28 | 2016-07-06 | Bioasis Technologies Inc. | Cns-targeted conjugates having modified fc regions and methods of use thereof |
| JP2016531915A (ja) | 2013-08-28 | 2016-10-13 | ステムセントリックス， インコーポレイテッド | 部位特異的抗体コンジュゲーション方法および組成物 |
| ES2927567T3 (es) | 2013-09-13 | 2022-11-08 | Beigene Switzerland Gmbh | Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico |
| CN111187348A (zh) | 2014-02-11 | 2020-05-22 | 西雅图基因公司 | 蛋白质的选择性还原 |
| WO2015127407A1 (en) | 2014-02-21 | 2015-08-27 | Stemcentrx, Inc. | Anti-dll3 antibodies and drug conjugates for use in melanoma |
| WO2016064749A2 (en) | 2014-10-20 | 2016-04-28 | Igenica Biotherapeutics, Inc. | Novel antibody-drug conjugates and related compounds, compositions, and methods of use |
-
2015
- 2015-09-03 TW TW104129184A patent/TW201617368A/zh unknown
- 2015-09-04 MA MA040612A patent/MA40612A/fr unknown
- 2015-09-04 SG SG11201701650PA patent/SG11201701650PA/en unknown
- 2015-09-04 KR KR1020177009300A patent/KR20170045351A/ko not_active Withdrawn
- 2015-09-04 PE PE2017000403A patent/PE20170776A1/es unknown
- 2015-09-04 WO PCT/US2015/048659 patent/WO2016037119A1/en not_active Ceased
- 2015-09-04 AU AU2015311743A patent/AU2015311743A1/en not_active Abandoned
- 2015-09-04 BR BR112017004444-7A patent/BR112017004444A2/en not_active Application Discontinuation
- 2015-09-04 EA EA201790529A patent/EA201790529A1/ru unknown
- 2015-09-04 CN CN201580060426.9A patent/CN107001454A/zh active Pending
- 2015-09-04 CR CR20170117A patent/CR20170117A/es unknown
- 2015-09-04 CA CA2959705A patent/CA2959705A1/en not_active Abandoned
- 2015-09-04 US US15/508,836 patent/US10428156B2/en not_active Expired - Fee Related
- 2015-09-04 JP JP2017512808A patent/JP2017535246A/ja active Pending
- 2015-09-04 MX MX2017002862A patent/MX2017002862A/es unknown
- 2015-09-04 EP EP15837897.6A patent/EP3189079A4/en not_active Withdrawn
-
2017
- 2017-02-27 IL IL250825A patent/IL250825A0/en unknown
- 2017-03-02 DO DO2017000052A patent/DOP2017000052A/es unknown
- 2017-03-03 PH PH12017500406A patent/PH12017500406A1/en unknown
- 2017-03-03 CL CL2017000506A patent/CL2017000506A1/es unknown
- 2017-03-08 ZA ZA2017/01674A patent/ZA201701674B/en unknown
- 2017-03-28 CO CONC2017/0003005A patent/CO2017003005A2/es unknown
-
2018
- 2018-06-22 CL CL2018001722A patent/CL2018001722A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017535246A5 (enExample) | ||
| US9353182B2 (en) | Anti-DLL3 antibodies | |
| ES2763548T3 (es) | Anticuerpos anti-TIM3 y procedimientos de uso | |
| JP2018127469A5 (enExample) | ||
| JP2016531915A5 (enExample) | ||
| JP2016531914A5 (enExample) | ||
| JP2019532056A5 (enExample) | ||
| KR20160070191A (ko) | 신규한 항-클라우딘 항체 및 사용 방법 | |
| JP2018529656A (ja) | 抗ｄｌｌ３抗体薬物コンジュゲートおよび使用方法 | |
| KR20160097336A (ko) | 신규 항-ｄｐｅｐ3 항체 및 이의 사용 방법 | |
| JP2016536020A5 (enExample) | ||
| CN110494448B (zh) | 包含抗-ly75抗体的医药组合 | |
| US20190201542A1 (en) | Anti-dll3 drug conjugates for treating tumors at risk of neuroendocrine transition | |
| KR20160047567A (ko) | 조작된 항-dll3 접합체 및 사용 방법 | |
| JP7657213B2 (ja) | 抗メソテリンエリブリン抗体－薬物コンジュゲート及び使用方法 | |
| KR20180088445A (ko) | 신규한 항-클라우딘 항체 및 사용 방법 | |
| JP2015509948A5 (enExample) | ||
| JP2020502271A (ja) | 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法 | |
| ES3007557T3 (en) | Anti-edb antibodies and antibody-drug conjugates | |
| KR20170045351A (ko) | 신규한 항-mfi2 항체 및 사용 방법 | |
| JP7578289B2 (ja) | Ｍｕｃ１８に特異的な抗体 | |
| AU2016355206A1 (en) | Novel anti-EMR2 antibodies and methods of use | |
| JP2019511199A (ja) | 新規の抗ｕｐｋ１ｂ抗体及び使用方法 | |
| AU2017261369A1 (en) | Novel anti-TNFRSF21 antibodies and methods of use | |
| JPWO2020143749A5 (enExample) |